Literature DB >> 15592266

Pregnancy discovered after smallpox vaccination: Is vaccinia immune globulin appropriate?

Peter G Napolitano1, Margaret A K Ryan, John D Grabenstein.   

Abstract

Smallpox vaccination just before conception or during pregnancy can result, in rare instances, in fetal vaccinia from viral infection of the fetus. Approximately 50 cases have been documented, despite literally billions of people having been vaccinated. This live viral vaccine has a wider array of rare but serious medical side effects (eg, eczema vaccinatum, progressive vaccinia, encephalitis, myopericarditis) compared with other vaccines that are given currently to the public. In response to recent world events, the Centers for Disease Control and Prevention and the United States Department of Defense established a preoutbreak smallpox vaccination program. Because no actual outbreak has yet occurred, some investigators have proposed prophylactic treatment with vaccinia immune globulin for pregnancies that are exposed to smallpox vaccine to prevent fetal vaccinia. We review the existing medical literature to access the risks of fetal vaccinia in these pregnancies and the controversy regarding the prophylactic use of vaccinia immune globulin.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15592266     DOI: 10.1016/j.ajog.2004.07.014

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  3 in total

Review 1.  Countermeasures and vaccination against terrorism using smallpox: pre-event and post-event smallpox vaccination and its contraindications.

Authors:  Hajime Sato
Journal:  Environ Health Prev Med       Date:  2010-12-21       Impact factor: 3.674

2.  Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections.

Authors:  Yuhong Xiao; Stuart N Isaacs
Journal:  Viruses       Date:  2010-10       Impact factor: 5.048

3.  Immunomodulator-based enhancement of anti smallpox immune responses.

Authors:  Osmarie Martínez; Eric Miranda; Maite Ramírez; Saritza Santos; Carlos Rivera; Luis Vázquez; Tomás Sánchez; Raymond L Tremblay; Eddy Ríos-Olivares; Miguel Otero
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.